Investigative Ophthalmology & Visual Science · 2013 · 87 citations · 38 references
MedicineOphthalmologyPharmacologyCell JunctionsMolecular Cell BiologySignal TransductionCorneal DiseaseCorneal PathologyCorneal PhysiologyEpithelial Barrier FunctionOcular BarriersOcular InflammationBarrier Disruption MechanismsBarrier Permeability RegulationCorneal Epithelial Barrier DisruptionCorneal Epithelial Barrier FunctionCorneal Epithelial DamageJunctional OrganizationTransepithelial Electrical ResistanceTransepithelial Resistance
PURPOSE: TNF-α disrupts the barrier function of cultured human corneal epithelial (HCE) cells. We investigated the effects of the cytoprotective drug rebamipide on this barrier disruption by TNF-α as well as on corneal epithelial damage in a rat model of dry eye. METHODS: The barrier function of HCE cells was evaluated by measurement of transepithelial electrical resistance. The distribution of tight-junction (ZO-1, occludin) and adherens-junction (E-cadherin, β-catenin) proteins, and the p65 subunit of nuclear factor-κB (NF-κB) was determined by immunofluorescence microscopy. Expression of junctional proteins as well as phosphorylation of the NF-κB inhibitor IκB-α and myosin light chain (MLC) were examined by immunoblot analysis. A rat model of dry eye was developed by surgical removal of exorbital lacrimal glands. RESULTS: Rebamipide inhibited the disruption of barrier function as well as the downregulation of ZO-1 expression, and the disappearance of ZO-1 from the interfaces of neighboring HCE cells induced by TNF-α. It also inhibited the phosphorylation and downregulation of IκB-α, the translocation of p65 to the nucleus, the formation of actin stress fibers, and the phosphorylation of MLC induced by TNF-α in HCE cells. Treatment with rebamipide eyedrops promoted the healing of corneal epithelial defects as well as attenuated the loss of ZO-1 from the surface of corneal epithelial cells in rats. CONCLUSIONS: Rebamipide protects corneal epithelial cells from the TNF-α-induced disruption of barrier function by maintaining the distribution and expression of ZO-1 as well as the organization of the actin cytoskeleton. Rebamipide is, thus, a potential drug for preventing or ameliorating the loss of corneal epithelial barrier function associated with ocular inflammation.
38
An SV40-immortalized human corneal epithelial cell line and its characterization.
Kaoru Araki‐Sasaki, Yuichi Ohashi, T Sasabe et al. · PubMed · 1995 · 738 citations
Fengjun Wang, W. Vallen Graham, Yingmin Wang et al. · American Journal Of Pathology · 2005 · 683 citations · Full text
Tear Cytokine Profiles in Dysfunctional Tear Syndrome
Helene Lam, Lauren Bleiden, Cintia S. de Paiva et al. · American Journal of Ophthalmology · 2008 · 490 citations · Full text